内科重症监护病房的患者血液管理专家共识

2020-02-28 中国输血协会 临床血液学杂志.2020,33(2):83-86.

分析内科重症监护病房(ICU)患者贫血、血小板减少及凝血功能障碍的病因。讨论内科ICU患者贫血、血小板减少及凝血功能障碍相应的防治原则,进一步形成符合内科ICU特点的患者血液管理(PBM)专家共识。从

中文标题:

内科重症监护病房的患者血液管理专家共识

发布机构:

中国输血协会

发布日期:

2020-02-28

简要介绍:

分析内科重症监护病房(ICU)患者贫血、血小板减少及凝血功能障碍的病因。讨论内科ICU患者贫血、血小板减少及凝血功能障碍相应的防治原则,进一步形成符合内科ICU特点的患者血液管理(PBM)专家共识。从而提高内科ICU的PBM 水平。

相关资料下载:
[AttachmentFileName(sort=1, fileName=)] GetToolGuiderByIdResponse(projectId=1, id=e77211c0018e5778, title=内科重症监护病房的患者血液管理专家共识, enTitle=, guiderFrom=临床血液学杂志.2020,33(2):83-86., authorId=0, author=, summary=分析内科重症监护病房(ICU)患者贫血、血小板减少及凝血功能障碍的病因。讨论内科ICU患者贫血、血小板减少及凝血功能障碍相应的防治原则,进一步形成符合内科ICU特点的患者血液管理(PBM)专家共识。从, cover=https://medsci-open-files.oss-cn-shanghai.aliyuncs.com/blood-1291132__340_1583770628000.jpg, journalId=0, articlesId=null, associationId=1014, associationName=中国输血协会, associationIntro=null, copyright=0, guiderPublishedTime=Fri Feb 28 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>分析内科重症监护病房(ICU)患者贫血、血小板减少及凝血功能障碍的病因。讨论内科ICU患者贫血、血小板减少及凝血功能障碍相应的防治原则,进一步形成符合内科ICU特点的患者血液管理(PBM)专家共识。从而提高内科ICU的PBM 水平。</p> </div> </div> </div>, tagList=[TagDto(tagId=12035, tagName=重症监护), TagDto(tagId=4273, tagName=血液)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=12035, guiderKeyword=重症监护, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1865, appHits=219, showAppHits=9, pcHits=609, showPcHits=1695, likes=2, shares=15, comments=7, approvalStatus=1, publishedTime=Tue Mar 10 12:00:13 CST 2020, publishedTimeString=2020-02-28, pcVisible=1, appVisible=1, editorId=1, editor=小M, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=7, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 10 00:17:19 CST 2020, updatedBy=1, updatedName=小M, updatedTime=Fri Jan 05 11:42:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207131, encodeId=1d41120e13125, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:46:46 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016420, encodeId=5bfd10164209e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:52 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016419, encodeId=2af2101641901, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:32 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880822, encodeId=15f688082264, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Aug 30 09:59:12 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2022-03-30 洁巴子

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207131, encodeId=1d41120e13125, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:46:46 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016420, encodeId=5bfd10164209e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:52 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016419, encodeId=2af2101641901, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:32 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880822, encodeId=15f688082264, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Aug 30 09:59:12 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2021-09-10 空空男人

    学习了,谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207131, encodeId=1d41120e13125, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:46:46 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016420, encodeId=5bfd10164209e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:52 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016419, encodeId=2af2101641901, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:32 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880822, encodeId=15f688082264, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Aug 30 09:59:12 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2021-09-10 空空男人

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207131, encodeId=1d41120e13125, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:46:46 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016420, encodeId=5bfd10164209e, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:52 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016419, encodeId=2af2101641901, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 22:38:32 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880822, encodeId=15f688082264, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Aug 30 09:59:12 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2020-08-30 120c570cm03暂无昵称

    学习了,谢谢

    0

拓展阅读

2015 BCSH英国重症监护的危重成人血液恶性肿瘤患者的管理指南

英国血液学标准委员会(BCSH,British Committee for Standards in Haematology) · 2015-06-20

2016 亚太和中东地区儿童重症监护最佳营养治疗共识

国外儿科相关医学专家组(统称) · 2016-10-01

2020 NICE指南:COVID-19快速指南—重症监护(NG.159)

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2020-03-20

2019 NICE 医疗技术创新简报:PulmoVista 500用于重症监护中的通气量监测【MIB203】

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2019-12-17

2023 AHA/NCS科学声明:心脏骤停后患者的重症监护管理

美国心脏协会(AHA,American Heart Association) · 2023-11-28